Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ (cabozantinib) and has also established a portfolio of other novel compounds, many of which are being advanced by partners as part of collaborations.
Michael M. Morrissey , Ph.D., the Exelixis’ president and chief executive officer, will present at the 15th Annual BIO CEO & Investor Conference at 8:30 a.m. EST on Tuesday, February 12, 2013 , in New York .
Dr. Morrissey will review the companys development plans, discuss the companys corporate strategy and financial outlook, and priorities for cabozantinib in 2013.